Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
  • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

• the present invention relates to the pharmaceutical formulations comprising cefdinir for use in the treatment of many diseases caused by gram positive and gram negative bacteria.
• Cefdinir shown by the Formula I below, was first disclosed in the application no. BE897864. In said document, it is mentioned that cefdinir is effective for use in the treatment of many diseases caused by gram positive and gram negative bacteria.
• Cefdinir is available in the market in capsule and suspension forms. It is necessary to orally administer the antibiotic drugs such as cefdinir, which are used for the treatment of the microbial infections, more than one time throughout the duration of the treatment. Although the oral administration of the drug is the most preferred route for the drug therapy, the antibiotic drugs with low bioavailability such as cefdinir are known to be quite inefficient for the use via oral route. In addition, a considerably high antibiotic plasma concentration is required in order for the antibiotics to reach the minimum inhibitory concentration (MIC) value against the bacteria. Accordingly, in order for the antibiotic drugs such as cefdinir to provide the desired therapeutic activity, they are required to be administered several times a day via the oral route. However, the necessity to administer the drugs suitable for oral use, containing cefdinir, more than one time a day leads to the inconvenience for the patient as well as the reduction of the patient compliance and thus the achievement of a lower therapeutic effect.
• the antibiotic drugs suitable for oral use, containing cefdinir more than one time
• the pharmaceutical formulations suitable for oral administration said formulations enabling the release of cefdinir in a controlled manner in the blood such that the active ingredient of cefdinir achieves the effective level in the blood for a long time.
• the inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are formulated in the form of modified release tablets and in case they comprise, at a ratio of 0,5-15%, a cellulose based polymer providing controlled release, the active ingredient of cefdinir reaches a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased.
• the present invention relates to the pharmaceutical formulations comprising cefdinir and the preparation of such formulations.
• the inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are prepared in the form of modified release tablets and in case they comprise, at a ratio of 0,5-1 %, a cellulose-based polymer providing controlled release, the active ingredient of cefdinir has a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased.
• the first feature of the present invention is the cefdinir formulations, which are formulated in modified release table form and which contain a cellulose-based controlled release polymer at a ratio of 0,5- 15%.
• Cefdinir contained in the pharmaceutical formulations according to the invention, may be present in the form of solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination of the same.
• the formulations according to the invention preferably comprise the cellulose-based controlled release polymer at a ratio of 1-10%, more preferably 2-8%.
• the cellulose-based polymer providing controlled release contained by the formulations according to the present invention, may be selected from a group consisting of carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hypromellose or the combinations thereof.
• hydroxypropyl methyl cellulose may be used as the cellulose-based polymer providing controlled release.
• the pharmaceutical formulations according to the invention may comprise hydroxypropyl methyl cellulose at a ratio of 2-8%.
• the formulation according to the invention may, in addition to cefdinir and the polymer providing controlled release, comprise at least one pharmaceutically acceptable auxiliary agent selected from a diluting agent, lubricating agent and film coating agent.
• the diluting agent contained by the formulation according to the invention may be selected from a group consisting of D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dibasic calcium phosphate anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and the combinations thereof.
• Cefdinir is known to have a low solubility in the body and therefore a low bioavailability.
• the inventors have observed in the studies they conducted that in the formulations prepared so that the ratio of the weight of the cellulose-based polymer providing controlled release.'the weight of the diluting agent will be between 3 : 1 and 1 : 10, preferably between 1 : 1 and 1 :8, the bioavailability of cefdinir increases, and therefore the effective drug level in the blood is more easily achieved and the therapeutic efficacy increases.
• the ratio of the weight of the cellulose-based polymer providing controlled release :the weight of the diluting agent is between 3:1 and 1 :10, preferably between 1 :1 and 1 :8.
• the lubricating agent contained by the formulations according to the invention may be selected from a group consisting of calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
• the film coating agent contained by the formulations according to the invention may be selected from a group consisting of titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or the combinations thereof.
• the film coating agent commercially available under the trademark Opadry Yellow® may be used.
• the pharmaceutical formulation according to the invention may comprise 0,5-95% cefdinir, 0,5-50% diluting agent, 0,5-15% controlled release polymer and 0,1-5% lubricating agent based on the total weight of the unit dose amount.
• the pharmaceutical formulation according to the invention may be obtained by a method comprising the steps of compacting the active ingredient cefdinir and the diluting agent, adding the polymer providing the controlled release to the compacted powder and mixing the same, adding the lubricating agent to this mixture and mixing again, pressing the final mixture in the form of a tablet and coating the pressed tablets with a coating solution comprising the coating agent.
• Another problem observed in the formulations according to the invention is the disintegration and fragmentation of the tablet during or after the pressing of the tablet. This problem causes the loss of material after the manufacture as well as the damage to the integrity of the tablet during the use, thereby leading the efficacy of the treatment to be adversely affected.
• the inventors have observed that in case the active ingredient and the diluting agent are compacted prior to being mixed with the controlled release polymer in order to prevent the disintegration of the tablet during or after the pressing of the same, no disintegration or fragmentation occurs in the tablet during and after the pressing of the same. Accordingly, a feature of the method employed for the preparation of the formulations according to the present invention is that cefdinir and the diluting agent are compacted prior to being mixed with the polymer that provides the controlled release.
• Another problem encountered during the manufacture of the pharmaceutical formulation according to the present invention is the agglomeration of the powder formulation.
• the inventors have observed that the formation of agglomerates is prevented by adding the polymer that provides the controlled release in the formulation according to the invention in two steps.
• Another feature of the manufacturing method employed for the preparation of the formulations according to the present invention is that the polymer that provides the controlled release is added in two steps.
• Another problem encountered during the manufacture of the formulations according to the present invention is the adhesion of the primary mixture in powder form to the components of the pressing machine during the pressing of the tablet, thereby leading to the loss of product.
• said problem has been solved owing to the ratio of the controlled 302
• release polymer added in the first step to the controlled release polymer added in the second step varying between 10:1 and 1:1 in the manufacturing method.
• the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 10:1 and 1 :1 in the manufacturing method employed for preparing said formulation.
• the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 7:1 and 2: 1 in the manufacturing method employed for preparing the formulations according to the present invention.
• the method for manufacturing the pharmaceutical formulations according to the invention comprises the steps of
• the pharmaceutical formulation according to the invention may be used in the prevention and treatment of many diseases caused by the gram positive and gram negative bacteria.
• Example 1 Formulation and process for preparing a cefdinir tablet
• cefdinir is compacted with the polymer providing the controlled release, the diluting agent is added and stirred in a mixer. The lubricating agent is added to this mixture and mixed again. The polymer providing the controlled release is added to the mixture obtained and the powder mixture thus obtained is pressed in tablet form. The pressed tablet is coated with a coating solution containing the film coating agent.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49753447

Family Applications (1)

Country Status (1)

Citations (4)

• 2013
  • 2013-09-30 WO PCT/TR2013/000302 patent/WO2014051532A1/fr not_active Ceased

Patent Citations (4)

Non-Patent Citations (1)

Similar Documents

Legal Events